Market Overview

TransEnterix, Inc. Appoints Eric Smith as Chief Commercial Officer

Share:

TransEnterix, Inc. (NYSE:TRXC), a medical device company that
is digitizing the interface between the surgeon and the patient to
improve minimally invasive surgery, today announced that Eric Smith has
been named Chief Commercial Officer, effective August 31, 2018.

In this newly created role, which will report directly to the Chief
Executive Officer, Mr. Smith will lead the company's global
commercialization efforts, with a focus on both strategic and tactical
execution efforts in sales, upstream and downstream marketing, field
clinical support and training with a focus on adoption and clinical
excellence.

"We are very excited to have Eric join the TransEnterix team. He brings
a wealth of experience commercializing innovative technologies on a
global scale," said Todd M. Pope, Chief Executive Officer of
TransEnterix. "As we look to drive widespread adoption of Senhance, we
believe that the addition of Eric's expertise in developing and driving
sales and marketing strategies will complement our existing team as we
continue to grow and increase our presence in the United States and
around the world."

Mr. Smith brings over two decades of medical technology experience to
TransEnterix, with over a decade of that focused on commercial
leadership and marketing strategy. Most recently, he was a Vice
President, Franchise Leader Acute Care at KCI Corporation, a developer
and manufacturer of wound healing products. While at KCI, he was
responsible for the development and commercialization of innovative
wound-care technologies on a global scale. Prior to joining KCI, Mr.
Smith served as Vice President of Global Strategic Marketing at Cordis
Corporation, a developer and manufacturer of medical devices for the
treatment of coronary and peripheral vascular diseases. He has also held
senior positions at Boston Scientific, C.R. Bard and Ernst & Young. He
received his Bachelor's degree from the University of New Hampshire and
his MBA from Babson College.

"I am extremely pleased to be joining TransEnterix during such an
exciting time in the company's history," said Smith. "Senhance is a
transformative technology with a large market opportunity, and I look
forward to contributing to the company's success and improving clinical
outcomes and patient care through the use of digital laparoscopy."

About TransEnterix

TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance™ Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for robotic
precision, haptic feedback, surgeon camera control via eye sensing and
improved ergonomics while offering responsible economics. The Senhance
Surgical System is available for sale in the US, the EU and select other
countries. For more information, visit www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to the Senhance Surgical
System and our current commercialization plans for this product. These
statements and other statements regarding our future plans and goals
constitute "forward looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe harbor
from liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which may
cause results to differ materially from expectations and include whether
Mr. Smith's expertise in developing and driving sales and marketing
strategies will complement TransEnterix's existing team as TransEnterix
continues to group and increase its presence in the United States and
around the world and whether Mr. Smith can contribute to TransEnterix's
success and improving clinical outcomes and patient care through the use
of digital laparoscopy. For a discussion of the risks and uncertainties
associated with TransEnterix's business, please review our filings with
the Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K for the year ended December 31, 2017, filed with the
SEC on March 8, 2018 and our other filings we make with the SEC. You are
cautioned not to place undue reliance on these forward looking
statements, which are based on our expectations as of the date of this
press release and speak only as of the origination date of this press
release. We undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.

View Comments and Join the Discussion!